University of Edinburgh scientists aim to boost genetic record analysis and dramatically reduce the time it takes to analyse millions of records.

Spinout company Omecu Ltd said it promises “wide-ranging benefits” in drug discovery and personalised medicine, while improving patient data security.

It is estimated that global human genomic data is doubling in size every seven months and may soon exceed other big data generators such as astronomy and the internet.

Although this data has the potential to revolutionise medicine and lead to new therapeutics and diagnostics, these benefits rely on the ability to unlock clinically actionable knowledge from the data.

The obstacles to accessing such data can prevent valuable information being extracted, by making the process very costly and time-consuming.

Omecu has developed a computation engine and web platform that will alter genetic record analysis and how genomic data is securely accessed and efficiently analysed.

The company draws on three years of research led by Dr Oriol Canela-Xandri at the MRC Human Genetics Unit, within the University of Edinburgh’s Institute of Genetics and Cancer, and Dr Konrad Rawlik at the University’s Roslin Institute.

Omecu was co-founded by Dr Canela-Xandri and Dr Rawlik alongside CEO Les Gaw and has been launched with the support of Edinburgh Innovations, the university’s commercialisation service.

Commenting on the news, Dr Canela-Xandri, Chancellor’s Fellow at Edinburgh Uni, said: “Our ambition is to create a paradigm shift where disease experts without a computer science background are able to easily query fragmented data sets, while cutting costs and without requiring the data-holding organisation to expose the data itself.

“Our recent funding awards mean we can now accelerate the development of our prototype and move towards a commercial product.”

Recommended

• Europol data pool must be deleted, says EU watchdog
• Equity firm Key to use Scots platform Aveni.ai to help vulnerable customers
• Cybersecurity risks a major global threat, World Economic Forum warns

Doctors Canela-Xandri and Rawlik have been supported by Edinburgh Innovations since 2019. They participated in the SETSquared ICURe programme in 2020 and received funding from Medical Research Council grants and the university’s Data-Driven Entrepreneurship Seed Fund and Fast Track Mentor initiatives, supported by the Scottish Funding Council.

The pair have recently been awarded £288,000 from Innovate UK, which will allow Omecu to refine its prototype and progress commercial engagement.

Dr George Baxter, CEO of Edinburgh Innovations, said: “Genomic data holds great promise for humanity, and the Omecu team have found a way to make it far easier for clinicians to make use of that data. We’re extremely proud to help researchers to launch a company with such potential.”

Professor Wendy Bickmore, Director of the MRC Human Genetics Unit at the University of Edinburgh, added: “Having a rapid way to extract useful knowledge from large genomic datasets will accelerate new discoveries and new treatments for human disease.”

Get the latest news from DIGIT direct to your inbox

Our newsletter covers the latest technology and IT news from Scotland and beyond, as well as in-depth features and exclusive interviews with leading figures and rising stars.

We will keep you up to date on the pivotal issues impacting the sector and let you know about key upcoming events to ensure that you don’t miss out on what’s going on across the Scottish tech community.

Click here to subscribe.